SG11201604541WA - Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist - Google Patents
Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistInfo
- Publication number
- SG11201604541WA SG11201604541WA SG11201604541WA SG11201604541WA SG11201604541WA SG 11201604541W A SG11201604541W A SG 11201604541WA SG 11201604541W A SG11201604541W A SG 11201604541WA SG 11201604541W A SG11201604541W A SG 11201604541WA SG 11201604541W A SG11201604541W A SG 11201604541WA
- Authority
- SG
- Singapore
- Prior art keywords
- methylpyrrolidin
- methanone
- triazol
- imidazol
- benzo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013060595 | 2013-12-03 | ||
| PCT/IB2014/066509 WO2015083071A1 (en) | 2013-12-03 | 2014-12-02 | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604541WA true SG11201604541WA (en) | 2016-07-28 |
Family
ID=52282787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604541WA SG11201604541WA (en) | 2013-12-03 | 2014-12-02 | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9790208B2 (en) |
| EP (1) | EP3077390B1 (en) |
| JP (1) | JP6091716B2 (en) |
| KR (1) | KR101839716B1 (en) |
| CN (1) | CN105793258B (en) |
| AU (1) | AU2014358743B2 (en) |
| CA (1) | CA2929720C (en) |
| CL (1) | CL2016001348A1 (en) |
| CY (1) | CY1119687T1 (en) |
| DK (1) | DK3077390T3 (en) |
| EA (1) | EA030109B1 (en) |
| ES (1) | ES2651508T3 (en) |
| HK (1) | HK1225736B (en) |
| HR (1) | HRP20171772T1 (en) |
| HU (1) | HUE034656T2 (en) |
| IL (1) | IL245922B (en) |
| LT (1) | LT3077390T (en) |
| MA (1) | MA39164B1 (en) |
| MX (1) | MX362701B (en) |
| MY (1) | MY176244A (en) |
| NO (1) | NO3077390T3 (en) |
| NZ (1) | NZ721493A (en) |
| PH (1) | PH12016500989A1 (en) |
| PL (1) | PL3077390T3 (en) |
| PT (1) | PT3077390T (en) |
| SA (1) | SA516371248B1 (en) |
| SG (1) | SG11201604541WA (en) |
| SI (1) | SI3077390T1 (en) |
| TW (1) | TWI636982B (en) |
| UA (1) | UA119151C2 (en) |
| WO (1) | WO2015083071A1 (en) |
| ZA (1) | ZA201604501B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104334544B (en) | 2012-06-04 | 2016-10-19 | 埃科特莱茵药品有限公司 | Benzimidazole proline derivative |
| TWI664177B (en) | 2013-12-03 | 2019-07-01 | 瑞士商愛杜西亞製藥有限公司 | Crystalline forms |
| UA119151C2 (en) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
| UA116053C2 (en) | 2013-12-04 | 2018-01-25 | Ідорсія Фармасьютікалз Лтд | Use of benzimidazole-proline derivatives |
| TWI756418B (en) | 2017-05-03 | 2022-03-01 | 瑞士商愛杜西亞製藥有限公司 | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
| BR112022020924A2 (en) | 2020-04-19 | 2023-02-14 | Idorsia Pharmaceuticals Ltd | METHODS OF TREATMENT OF A SLEEP DISORDER, DAYTIME DREAMINESS IN AN INDIVIDUAL, INSOMNIA, AND, DARIDOXANT IN FREE OR PHARMACEUTICALLY ACCEPTABLE SALT FORM |
| CN115925699B (en) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | Fused ring compound with analgesic activity and preparation method and application thereof |
| CN117736193A (en) * | 2023-12-19 | 2024-03-22 | 南京知和医药科技有限公司 | Deuterated condensed ring compound and preparation method and application thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
| EP1289955B1 (en) | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| CA2425185A1 (en) | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
| WO2002044172A1 (en) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Morpholine derivatives as antagonists of orexin receptors |
| EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| EP1956020A3 (en) | 2001-05-05 | 2008-08-20 | Smithkline Beecham Plc | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| ES2266549T3 (en) * | 2001-06-28 | 2007-03-01 | Smithkline Beecham Plc | CYCLIC N-AROIL-AMINA DERIVATIVES AS AN OREXINE RECEIVER ANTAGONISTS. |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| JP2006504695A (en) | 2002-09-18 | 2006-02-09 | グラクソ グループ リミテッド | N-aroyl cyclic amines as orexin receptor antagonists |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| NZ550216A (en) | 2004-03-01 | 2009-08-28 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| EA015256B1 (en) | 2006-03-15 | 2011-06-30 | Актелион Фармасьютикалз Лтд. | Tetrahydroisoquinoline derivatives to enhance memory function |
| WO2007135527A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
| EP2069332B1 (en) | 2006-08-15 | 2011-03-02 | Actelion Pharmaceuticals Ltd. | Azetidine compounds as orexin receptor antagonists |
| ES2350460T3 (en) | 2006-09-29 | 2011-01-24 | Actelion Pharmaceuticals Ltd. | DERIVATIVES OF 3-AZA-BICICLO [3.1.0] HEXANO. |
| PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
| AR064561A1 (en) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (en) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others. |
| DE602008002934D1 (en) | 2007-05-14 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 2-CYCLOPROPYLTHIAZOLDERIVATE |
| CA2687230A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| JP2010531871A (en) | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | 3-Aza-bicyclo [3.3.0] octane compound |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| CN101796053A (en) | 2007-07-03 | 2010-08-04 | 葛兰素集团有限公司 | Piperidine derivatives useful as orexin receptor antagonists |
| TW200904799A (en) | 2007-07-27 | 2009-02-01 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| BRPI0814593A2 (en) | 2007-07-27 | 2015-01-20 | Actelion Pharmaceuticals Ltd | COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND. |
| EP2207778A2 (en) | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| PE20091010A1 (en) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | TETRAHYDROQUINOLINE DERIVATIVES |
| JP2011512400A (en) | 2008-02-21 | 2011-04-21 | アクテリオン ファーマシューティカルズ リミテッド | 2-Aza-bicyclo [2.2.1] heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CN102083827A (en) | 2008-07-07 | 2011-06-01 | 埃科特莱茵药品有限公司 | Thiazolidine compounds as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358713A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| KR20110091582A (en) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | N-{[(1r,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
| CA2745420A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| GB0823467D0 (en) * | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| JP2012524760A (en) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | 3-Azabicyclo [4.1.0] heptane used as an orexin antagonist |
| CN103079563B (en) | 2010-08-24 | 2015-07-08 | 埃科特莱茵药品有限公司 | Proline sulfonamide derivatives as orexin receptor antagonists |
| CA2815179A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| EP2675801B1 (en) | 2011-02-18 | 2015-04-08 | Actelion Pharmaceuticals Ltd. | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| SG11201401665WA (en) | 2011-11-08 | 2014-09-26 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| DK2838900T3 (en) | 2012-04-17 | 2019-10-14 | Gilead Sciences Inc | RELATIONS AND PROCEDURES FOR ANTIVIRAL TREATMENT |
| CN104334544B (en) | 2012-06-04 | 2016-10-19 | 埃科特莱茵药品有限公司 | Benzimidazole proline derivative |
| EA201500399A1 (en) | 2012-10-10 | 2015-09-30 | Актелион Фармасьютиклз Лтд. | OREXIN RECEPTOR ANTAGONISTS, WHICH ARE REPRESENTING DERIVATIVES OF [ORTO-BI- (HETERO) ARYL] - [2- (META-BI- (HETERO) ARYL) PYRROLIDIN-1-IL] METHANON |
| CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| UA119151C2 (en) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
| TWI664177B (en) | 2013-12-03 | 2019-07-01 | 瑞士商愛杜西亞製藥有限公司 | Crystalline forms |
| UA116053C2 (en) | 2013-12-04 | 2018-01-25 | Ідорсія Фармасьютікалз Лтд | Use of benzimidazole-proline derivatives |
-
2014
- 2014-02-12 UA UAA201607115A patent/UA119151C2/en unknown
- 2014-12-02 SI SI201430453T patent/SI3077390T1/en unknown
- 2014-12-02 US US15/101,832 patent/US9790208B2/en active Active
- 2014-12-02 MY MYPI2016701995A patent/MY176244A/en unknown
- 2014-12-02 EA EA201600436A patent/EA030109B1/en not_active IP Right Cessation
- 2014-12-02 CA CA2929720A patent/CA2929720C/en active Active
- 2014-12-02 CN CN201480065749.2A patent/CN105793258B/en active Active
- 2014-12-02 SG SG11201604541WA patent/SG11201604541WA/en unknown
- 2014-12-02 KR KR1020167017678A patent/KR101839716B1/en active IP Right Grant
- 2014-12-02 PT PT148241086T patent/PT3077390T/en unknown
- 2014-12-02 MA MA39164A patent/MA39164B1/en unknown
- 2014-12-02 NO NO14824108A patent/NO3077390T3/no unknown
- 2014-12-02 WO PCT/IB2014/066509 patent/WO2015083071A1/en active Application Filing
- 2014-12-02 DK DK14824108.6T patent/DK3077390T3/en active
- 2014-12-02 AU AU2014358743A patent/AU2014358743B2/en active Active
- 2014-12-02 EP EP14824108.6A patent/EP3077390B1/en active Active
- 2014-12-02 TW TW103141830A patent/TWI636982B/en active
- 2014-12-02 JP JP2016536106A patent/JP6091716B2/en active Active
- 2014-12-02 HU HUE14824108A patent/HUE034656T2/en unknown
- 2014-12-02 ES ES14824108.6T patent/ES2651508T3/en active Active
- 2014-12-02 NZ NZ721493A patent/NZ721493A/en unknown
- 2014-12-02 MX MX2016007216A patent/MX362701B/en active IP Right Grant
- 2014-12-02 PL PL14824108T patent/PL3077390T3/en unknown
- 2014-12-02 LT LTEP14824108.6T patent/LT3077390T/en unknown
-
2016
- 2016-05-26 PH PH12016500989A patent/PH12016500989A1/en unknown
- 2016-05-30 IL IL24592216A patent/IL245922B/en active IP Right Grant
- 2016-06-01 SA SA516371248A patent/SA516371248B1/en unknown
- 2016-06-02 CL CL2016001348A patent/CL2016001348A1/en unknown
- 2016-07-01 ZA ZA2016/04501A patent/ZA201604501B/en unknown
- 2016-12-14 HK HK16114201A patent/HK1225736B/en unknown
-
2017
- 2017-09-12 US US15/702,281 patent/US10023560B2/en active Active
- 2017-11-16 HR HRP20171772TT patent/HRP20171772T1/en unknown
- 2017-12-12 CY CY20171101302T patent/CY1119687T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225736B (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
| HK1225731B (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists | |
| DK2878598T3 (en) | Crystalline Form of 4- [5- (PYRIDIN-4-YL) -1H-1,2,4-TRIAZOL-3-YL] PYRIDIN-2-CARBONITRIL | |
| LT2862860T (en) | 1,3-oxazolidine or 1,3-oxazinane compounds as orexin receptor antagonists | |
| CO7081154A2 (en) | New polymorphic crystalline forms of 5- (2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1- (r) -hydroxyethyl) -8-hydroxyquinolin-2 (1h) -one, heminapadisilate as b2 adrenergic receptor agonist | |
| HRP20130657T1 (en) | Imidazole derivatives as mglur5 antagonists | |
| TH1601000390A (en) | Derivative salts 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2-(1H)-one(2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1H)-one), which has both muscarinic effects Receptor Antagonists and (Beta)2 Adrenergic Receptor Agonists |